View this WAPPS News Article
WAPPS-Hemo is pleased to announce the launch of two new population pharmacokinetic (PK) models for ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) that use the one-stage and chromogenic assays.
Looking for an opportunity to participate in a clinical trial for WAPPS? There are currently two trials that are recruiting.
Currently available PK models in WAPPS-Hemo. New models are added when sufficient data has been collected.
Publications by the core WAPPS-Hemo team, the WAPPS-Hemo Research Network and other related publication sources.
We have been receiving questions regarding Afstyla and whether WAPPS-Hemo already multiplies the resultant measurements by a factor of 2 if a one-stage clotting assay was used. Conversely, the scientific community recommends the use of chromogenic assays or to “calibrate” the clotting assays with a specific standard.